Simple Summary Interstitial lung disease is a group of diseases characterized by chronic
lung inflammation that can be related to oncological treatments, such as traditional …

In this coronavirus 2019 (COVID-19) era, when pneumonitis occurs in patients with lung
cancer receiving immune checkpoint inhibitors (ICIs), a major challenge is to make a rapid …

Abstract The Coronavirus disease (COVID-19) pandemic is disrupting our health
environment. As expected, studies highlighted the great susceptibility of cancer patients to …

Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection due to hospital contact and an immunological system that can be …

Myriad drugs including antineoplastic agents, antiinflammatory agents, cardiovascular
agents, and antimicrobials have been associated with pulmonary complications of various …

It was December 2019 when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) was identified for the first time in Wuhan, China. Since then, the outbreak has quickly …

The rapid emergence of COVID-19 pandemics worldwide is of particular concern for fragile
populations who are more at risk of acute respiratory distress syndrome and death. Patients …

Abstract Purpose of Review Since the past year, the fast spread of coronavirus disease 2019
(COVID-19) has represented a global health threat, especially for cancer patients, that has …

5. Waiting for the results of molecular testing in metastatic nonsmall-cell lung cancer
(NSCLC): As is done in routine clinical practice, for treatment naïve patients with metastatic …

The outbreak of the Coronavirus disease (COVID-19) pandemic has deeply challenged
healthcare systems and care of patients with cancer. Phase 1 studies are among the most …